Google became the latest tech giant and cloud service provider to sign agreements to procure power generated by nuclear reactors in October, and that's good news for the industry at large.

Eli Lilly and its investors this past week learned a hard lesson: The sky is no longer the limit when it comes to sales of its blockbuster glucagon-like peptide 1 (GLP-1) drugs for diabetes and ...